Skip to main content

Table 1 Summary of Patient Data

From: Functional acute acquired comitant esotropia: clinical characteristics and efficacy of single Botulinum toxin type A injection

Patient No.

Age

Daily

Near

Work

(hour)

Spherical

Equivalent (D)

Pupillary

Distance (mm)

Reciprocal stereoacuity

Deviation (PD)

Convergence (PD)

Divergence (PD)

Vergence (PD)

Accommodation (D)

Gradient AC/A (PD/D)

OD

OS

Pre-

BTXA

Final

Pre-BTXA

Distance

Final

Distance

Pre-BTXA

Near

Final

Near

Pre-BTXA

Distance

Final

Distance

Pre-BTXA

Near

Final

Near

Pre-BTXA

Distance

Final

Distance

Pre-BTXA

Near

Final

Near

Pre-BTXA

Distance

Final

Distance

Pre-BTXA

Near

Final

Near

Pre-BTXA

OD

Final

OD

Pre-BTXA

OS

Final

OS

Pre-BTXA

Final

1

32

8

-3.375

-3.125

59

0.014

0.014

10

0

20

6

9

12

10

25

7

8

7

10

16

20

17

35

2.25

7

2.5

6.75

9

10

2

35

10

-5.25

-4.5

57

0.014

0.014

25

16

24

20

22

20

14

40

12

20

6

25

34

40

20

65

3.75

7.25

3.25

7.75

5

3

3

32

13

-4.25

-4

58

0.014

0.014

6

1

6

0.5

16

40

20

25

10

15

10

5

26

55

30

30

10

15.5

9

16.5

9

7

4

17

11

-4.25

-4.675

57

0.005

0.014

40

20

45

20

14

40

14

30

8

8

1

14

22

48

15

44

8.5

16.25

9

18

9

10

5

16

9

-6

-6.25

59

0.000

0.007

35

20

40

20

30

40

35

34

12

12

12

16

42

52

47

50

2

19

1.5

19.5

14

5

6

35

12

-0.25

-1

66

0.033

0.003

28

20

20

10

3

20

30

30

16

20

18

20

19

40

48

50

6.5

8.25

6.25

9

5

3

7

14

9

-3.75

-4

59

0.000

0.014

40

14

45

16

14

18

14

25

8

12

1

16

22

30

15

41

1

7.5

1

5.25

8

4

8

29

14

-4

-3.75

56

0.014

0.033

12

4

10

0

25

30

18

43

4

6

6

6

29

36

24

49

11

11.75

11

12

13

7

9

28

16

-7.875

-8.25

63

0.025

0.010

30

25

30

30

14

14

35

16

2

12

20

12

16

26

55

28

4.75

6.75

4

9.25

5

3

10

31

18

-7.75

-7.75

66

0.010

0.014

25

6

25

12

16

20

30

40

12

20

16

35

28

40

46

75

8.75

12.5

8.25

12.5

10

4

11

19

13

-7

-6

61

0.000

0.005

45

20

40

25

4

30

16

45

5

16

1

16

9

46

17

61

8.75

12.5

8.5

13

10

8

12

37

17

-4.75

-3.5

61

0.000

0.014

20

8

30

12

18

40

40

50

8

17

10

7

26

57

50

57

6.75

10.25

8

11

6

4

13

25

14

-3.75

-4

65

0.033

0.014

12

5

18

0

14

15

18

18

2

6

7

3

16

21

25

21

13.25

8.5

13.75

8

7

5

14

26

14

0

0

63

0.014

0.014

25

14

20

14

8

16

18

20

4

8

5

5

12

24

23

25

7.5

8.25

7.5

7

5

3

15

27

15

-4.125

-3.5

58

0.007

0.014

20

6

20

7

6

25

8

35

6

16

6

10

12

41

14

45

5

10.5

4.5

10.25

5

5

16

21

12

-4.25

-4.75

59

0.007

0.007

18

3

20

5

18

20

30

20

8

6

6

7

26

26

36

27

11.75

10.5

11.5

10.75

2

2

17

38

13

-4.25

-3.75

58

0.014

0.007

20

16

20

16

10

14

18

20

4

12

8

18

14

26

26

38

6

5.75

6

5.5

5

7

18

27

18

0

0

66

0.000

0.010

16

4

25

3

0.5

8

9

10

3

8

9

8

3.5

16

18

18

4.25

5.5

4.5

6.25

7

3

19

23

9

-5.25

-1.5

57

0.014

0.007

45

14

45

14

40

45

40

45

14

12

8

14

54

57

48

59

13

10.25

7.75

10

10

4

20

23

14

-3.75

-6.75

58

0.000

0.003

25

7

27

1

16

20

12

25

5

8

6

8

21

28

18

33

11.75

9.75

13.75

10.75

5

5

21

15

11

-4.875

-3.125

57

0.000

0.005

30

14

35

16

12

35

20

40

5

5

10

12

17

40

30

52

9.25

13.75

10.25

14.5

10

8

22

29

13

-7

-6.875

59

0.040

0.014

25

12

45

14

25

20

20

30

5

6

6

10

30

26

26

40

11.75

9.75

10.5

9.5

5

6

  1. BTXA Botulinum toxin type A, Final The last follow-up at the 3 months after injection, OD Oculus dexter, OS Oculus sinister, PD Prism diopters, D Diopters. Patient 4,5,9,11,14,21 and 22 had persistent diplopia at 3 months after injection